Immunomodulation by targeted anticancer agents

Giulia Petroni; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi

doi:10.1016/j.ccell.2020.11.009

Immunomodulation by targeted anticancer agents

Cancer Cell. 2021 Mar 8;39(3):310-345. doi: 10.1016/j.ccell.2020.11.009. Epub 2020 Dec 17.

Authors

Giulia Petroni¹, Aitziber Buqué¹, Laurence Zitvogel², Guido Kroemer³, Lorenzo Galluzzi⁴

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
² Gustave Roussy Cancer Center, Villejuif, France; INSERM U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France; Faculty of Medicine, Paris-Saclay University, Le Kremlin-Bicêtre, France.
³ Equipe Labellisée Par La Ligue Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China; Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. Electronic address: [email protected].
⁴ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA; Université de Paris, Paris, France. Electronic address: [email protected].

PMID: 33338426
DOI: 10.1016/j.ccell.2020.11.009

Abstract

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.

Keywords: BRAF; CD8(+) cytotoxic T lymphocytes; CDK4/CDK6; CGAS signaling; DNA damage response; EGFR; KRAS; T(REG) cells; TGF-β; immune checkpoint blockers; immunogenic cell death.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Animals
Antineoplastic Agents / immunology*
Disease Progression
Humans
Immunomodulation / immunology*
Neoplasms / immunology*
Neoplasms / therapy*

Substances

Antineoplastic Agents